Xtreem Pulse, a company based in New York City, was cleared by the FDA to introduce its PureFlow system in the U.S. as a treatment option for patients with chronic stable angina that is refractory to optimal anti-anginal medical therapy while not being able to receive a revascularization procedure. The company says the device is actually intended (Read more...)